[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse FGB

Summary
SymbolFGB
Namefibrinogen beta chain
Aliases fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location4q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF08702 Fibrinogen alpha/beta chain family
PF00147 Fibrinogen beta and gamma chains
Function

Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002576 platelet degranulation
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002793 positive regulation of peptide secretion
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006887 exocytosis
GO:0006959 humoral immune response
GO:0007160 cell-matrix adhesion
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008015 blood circulation
GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors
GO:0009306 protein secretion
GO:0009914 hormone transport
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010720 positive regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0010817 regulation of hormone levels
GO:0015833 peptide transport
GO:0016485 protein processing
GO:0017157 regulation of exocytosis
GO:0019229 regulation of vasoconstriction
GO:0019730 antimicrobial humoral response
GO:0019731 antibacterial humoral response
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0022604 regulation of cell morphogenesis
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030168 platelet activation
GO:0030193 regulation of blood coagulation
GO:0030195 negative regulation of blood coagulation
GO:0030198 extracellular matrix organization
GO:0031589 cell-substrate adhesion
GO:0031638 zymogen activation
GO:0031639 plasminogen activation
GO:0032102 negative regulation of response to external stimulus
GO:0034109 homotypic cell-cell adhesion
GO:0034113 heterotypic cell-cell adhesion
GO:0034114 regulation of heterotypic cell-cell adhesion
GO:0034116 positive regulation of heterotypic cell-cell adhesion
GO:0034446 substrate adhesion-dependent cell spreading
GO:0035150 regulation of tube size
GO:0042310 vasoconstriction
GO:0042730 fibrinolysis
GO:0042742 defense response to bacterium
GO:0042886 amide transport
GO:0043062 extracellular structure organization
GO:0043152 induction of bacterial agglutination
GO:0043410 positive regulation of MAPK cascade
GO:0044057 regulation of system process
GO:0044320 cellular response to leptin stimulus
GO:0044321 response to leptin
GO:0045055 regulated exocytosis
GO:0045785 positive regulation of cell adhesion
GO:0045907 positive regulation of vasoconstriction
GO:0045921 positive regulation of exocytosis
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046887 positive regulation of hormone secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050819 negative regulation of coagulation
GO:0050878 regulation of body fluid levels
GO:0050880 regulation of blood vessel size
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0051258 protein polymerization
GO:0051592 response to calcium ion
GO:0051604 protein maturation
GO:0060627 regulation of vesicle-mediated transport
GO:0061041 regulation of wound healing
GO:0061045 negative regulation of wound healing
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070527 platelet aggregation
GO:0070555 response to interleukin-1
GO:0071347 cellular response to interleukin-1
GO:0072376 protein activation cascade
GO:0072378 blood coagulation, fibrin clot formation
GO:0072577 endothelial cell apoptotic process
GO:0090066 regulation of anatomical structure size
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:0090277 positive regulation of peptide hormone secretion
GO:0097191 extrinsic apoptotic signaling pathway
GO:0098542 defense response to other organism
GO:1900024 regulation of substrate adhesion-dependent cell spreading
GO:1900026 positive regulation of substrate adhesion-dependent cell spreading
GO:1900046 regulation of hemostasis
GO:1900047 negative regulation of hemostasis
GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:1903522 regulation of blood circulation
GO:1903524 positive regulation of blood circulation
GO:1903532 positive regulation of secretion by cell
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904036 negative regulation of epithelial cell apoptotic process
GO:1904951 positive regulation of establishment of protein localization
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000352 negative regulation of endothelial cell apoptotic process
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function GO:0030674 protein binding, bridging
GO:0050839 cell adhesion molecule binding
GO:0051087 chaperone binding
GO:0060090 binding, bridging
Cellular Component GO:0005577 fibrinogen complex
GO:0005938 cell cortex
GO:0009897 external side of plasma membrane
GO:0030141 secretory granule
GO:0031091 platelet alpha granule
GO:0031093 platelet alpha granule lumen
GO:0031983 vesicle lumen
GO:0034774 secretory granule lumen
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0072562 blood microparticle
GO:0098552 side of membrane
GO:0099503 secretory vesicle
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG hsa04610 Complement and coagulation cascades
hsa04611 Platelet activation
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-422475: Axon guidance
R-HSA-140875: Common Pathway of Fibrin Clot Formation
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1474244: Extracellular matrix organization
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-140877: Formation of Fibrin Clot (Clotting Cascade)
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-354194: GRB2
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-354192: Integrin alphaIIb beta3 signaling
R-HSA-216083: Integrin cell surface interactions
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5674135: MAP2K and MAPK activation
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-6802957: Oncogenic MAPK signaling
R-HSA-6802955: Paradoxical activation of RAF signaling by kinase inactive BRAF
R-HSA-76009: Platelet Aggregation (Plug Formation)
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-5686938: Regulation of TLR by endogenous ligand
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-6802952: Signaling by BRAF and RAF fusions
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-6802949: Signaling by RAS mutants
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-6802948: Signaling by high-kinase activity BRAF mutants
R-HSA-6802946: Signaling by moderate kinase activity BRAF mutants
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-372708: p130Cas linkage to MAPK signaling for integrins
Summary
SymbolFGB
Namefibrinogen beta chain
Aliases fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location4q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FGB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolFGB
Namefibrinogen beta chain
Aliases fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location4q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FGB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFGB
Namefibrinogen beta chain
Aliases fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location4q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FGB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.3590.182
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0320.984
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)872.4050.0746
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1310.89
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2940.825
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0610.968
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8760.499
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8410.669
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5930.76
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8020.758
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0460.99
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-1.4930.00756
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FGB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFGB
Namefibrinogen beta chain
Aliases fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location4q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FGB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFGB
Namefibrinogen beta chain
Aliases fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location4q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FGB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FGB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFGB
Namefibrinogen beta chain
Aliases fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location4q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FGB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFGB
Namefibrinogen beta chain
Aliases fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location4q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FGB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFGB
Namefibrinogen beta chain
Aliases fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location4q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FGB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFGB
Namefibrinogen beta chain
Aliases fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location4q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FGB collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FGB.
ID Name Drug Type Targets #Targets
DB00364SucralfateSmall MoleculeEGF, FGA, FGB, FGF2, FGG5
DB04919AlfimepraseBiotechFGA, FGB2
DB11311ProthrombinBiotechCPB2, F13A1, FGA, FGB4
DB13151Anti-inhibitor coagulant complexBiotechF10, F13A1, F2, F5, F7, F8, FGA, FGB8